Literature DB >> 10583884

Epitope-specific glutamic acid decarboxylase-65 autoantibodies in intravenous immunoglobulin preparations.

W Hao1, C Davis, T Daniels, C S Hampe, A Lernmark.   

Abstract

Intravenous immunoglobulin (IVIG) has been used to treat many autoimmune disorders including Stiff-Man Syndrome (SMS). SMS is a neurological disorder associated with an immune-mediated deficiency of gamma-aminobutyric acid (GABA) due to autoantibodies against the GABA synthesizing enzyme glutamic acid decarboxylase-65 (GAD65). GAD65 autoantibodies are present among 1-2% of healthy individuals. It can therefore not be excluded that GAD65 autoantibodies may be present in IVIG, which is prepared from multiple blood donors. We report here that GAD65 but not IA-2 autoantibodies were present in commercial IVIG preparations. The presence of autoantibodies may affect the outcome of IVIG treatment and screening commercial preparations of IVIG for GAD65 autoantibodies is therefore recommended before treating patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583884     DOI: 10.1046/j.1365-3148.1999.00214.x

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


  2 in total

1.  Detection of anti-glutamic acid decarboxylase antibodies in immunoglobulin products.

Authors:  Tukisa D Smith; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol Pract       Date:  2017-06-29

2.  Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificity.

Authors:  Thomas Grüter; Anthonina Ott; Wolfgang Meyer; Sven Jarius; Markus Kinner; Jeremias Motte; Kalliopi Pitarokoili; Ralf Gold; Lars Komorowski; Ilya Ayzenberg
Journal:  J Neurol       Date:  2019-11-14       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.